Status:
COMPLETED
Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation
Lead Sponsor:
Weill Medical College of Cornell University
Conditions:
Kidney Failure, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Tacrolimus (Prograf) belongs to a class of medications known as the calcineurin inhibitors. It is a maintenance drug that is used to prevent rejection in kidney, liver, and heart transplant recipients...
Detailed Description
Tacrolimus (Prograf) belongs to a class of medications known as the calcineurin inhibitors. It is a maintenance drug that is used to prevent rejection in kidney, liver, and heart transplant recipients...
Eligibility Criteria
Inclusion
- Adult patients awaiting kidney transplantation aged ≥ 18 years
Exclusion
- Patients concurrently treated with medications that interact with tacrolimus (other than clotrimazole)
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00629122
Start Date
February 1 2008
End Date
December 1 2009
Last Update
June 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NewYork-Presbyterian Hospital
New York, New York, United States, 10065